Eric Lefkofsky Contributes Actively in Precision Medicine

In 2015 Eric Lefkosky co-founded Tempus Labs to help break down the large sets of data available in the health care system. The technology firm runs DNA/RNA sequencing protocols that enable the addition of molecular data. Based in Chicago, Tempus Labs seeks to provide physicians with the information of cancer patients that can be used in developing customized intervention methods.

The firm hopes to take part in precision medicine that is gaining popularity among a lot of medical quarters. Data pipelines were created to have molecular and clinical data collected and analysed. This will enable the consolidation of the patient’s health data. The data gives physicians and health caregivers an opportunity to track the medication given to patients and their responses to the same. Better and more precise treatment options will be offered to the patients.

Its activities have seen Tempus be recognised among the top ten Chicago health techs. It has also partnered with academic institutions as well as health facilities including the Comprehensive Cancer Centers. Most of the patients from the health centers have their genomic material sequenced at Tempus. The results along with the clinical information of the patient are used to create a report that will guide the decision of the healthcare givers. The progress and effective mitigation of cancer mutations can be traced using this method.

Biological markers including brain alterations have recently been used to define Alzheimer’s disease. This is not similar to the symptoms like memory loss that were used in the past. The use of symptoms meant that patients started receiving treatment and special care when the disease was at an advanced stage. The new method will allow for early diagnosis that has great benefits. Brain scans will ensure that the accuracy of the diagnosis and prognosis of the disease are enhanced.

Eric Lefkofsky has made a name for himself among the entrepreneurs of Chicago. He has co-founded numerous firms including Uptake Technologies, Mediaocean, Innerworkings and Lightbank. He supports initiatives to better lives with the Lefkofsky Family Foundation that he co-chairs with his wife Liz.

The Steppenwolf Theatre Company of Chicago appointed him chair of its board of Trustees. He has authored Accelerated Disruption. He has also given generously to philanthropic work including to the Lurie Children’s Hospital.

To know more click: here.

Eric Lefkofsky: Why Harnessing Data Can Change Treatment Mechanisms

Eric Lefkofsky is passionate about using big data to provide alternative solutions. For this reason, he has leverage data to assist in the diagnosis and treatment of cancer. Eric Lefkofsky emphasizes the importance of gathering molecular and clinical data in prognosis. Clinical data collection entails phenotypic information, outcome and therapeutic response while molecular data gives genomic information. Data on the patient, drug history and response and molecular response can help doctors and physicians analyze the risk of treatment, deduce answers for the differences in the response of patients and help in further research.

After experiencing his wife’s battle with breast cancer, Eric realized that data collection and digital technology was not being utilized fully in the healthcare sector. Surprisingly, a lot of data was generated on patient information and treatments but there was no mechanism that allowed the professionals to synchronize and use the data effectively.

The need to make sense of data led to the formation of Tempus, a company that specializes in precision medicine. Erick Lefkofsky is the Chief executive officer and co-founder of the company. The primary objective of Tempus is to revolutionize cancer care. As such, they have created an analytics software that enables outlines and evaluates the clinical and molecular information. The company has had to overcome challenges such as affordability and accessibility of the data at the initial stage. Plus, processing the physician notes that are the primary source of information about the patient’s condition, can be difficult to understand and follow. Nevertheless, the Tempus software allows optical character recognition and processing of natural language. Eric believes that the use of data enabled treatments will increase in future as technology advances. He is hopeful that improvements in genome sequencing will further cancer research and treatment.

Eric Lefkofsky is an alumnus of the University of Michigan. He volunteers on the board of directors of the Art Institute of Chicago and Lurie’s Children’s Memorial Hospital. He lectured at the Kellogg School of Management in Northwestern Univerity and the Depaul University Kellstadt Graduate School of Business. Currently, he is a professor at the Booth School of Business, University of Chicago.

Read More:

How Clay Siegall has Advanced Cancer Treatment

Seattle Genetics is an American firm that is recognized due to its commitment to the development of targeted cancer therapies. The company has made significant accomplishments, and it is managed by Clay Siegall who is also its co-founder. Siegall worked with various scientists in establishing the firm in 1998, and he was appointed as the chairman of its board. He has led the company in making significant scientific inventions that are dedicated to saving the lives of people who have cancer. Seattle Genetics has managed to develop antibody-drug conjugates (ADCs), which serve as safe and effective cures for cancer.

Seattle Genetics has developed drugs such as AbbVie, Roche, Pfizer, and GlaxoSmithKline by using the ADC technology, and they are all FDA-approved. Clay worked for different institutions before establishing Seattle Genetics. He served as a researcher in organizations such as the National Cancer Institute, Bristol-Myers Squibb Pharmaceutical Research Institute, and National Institute of Health. Clay has been appointed to sit on the management boards of private pharmaceutical companies such as Ultragenyx, Mirna, Therapeutics, and BioPharmaceuticals. He completed his undergraduate education in zoology from the University of Maryland and was also awarded a Ph.D. atGeorge Washington University.

The research work of Seattle Genetics has significantly bettered cancer treatment, and this has made Siegall be highly respected in the pharmaceuticals industry. In 2013, Mirna Therapeutics appointed him to act as its outside board member. He has been guiding the company on the development of micro-RNA-based therapeutics. According to Clay, therapeutics that are created from micro-RNA play a great role in cancer treatment. He has been working with professional at Mirna Therapeutics, and he believes that they are highly productive. Siegall has made several discoveries while at Seattle Genetics, and he currently holds 15 patents. He has also written several research books.

Seattle Genetics has grown over the years, and it currently sells its ADC drugs in the international markets. More the 21 drugs have been developed from the ADC technology that it discovered. To date, the company has generated more than $675 million from selling its products. Its researchers are working to establish personalized treatments for patients.

Mikhail Blagloskloony: The Future of Cancer Treatment and Anti-Aging Medication

Aging is an increase in one’s probability of death as they age. There is no case of a person dying from health or without any cause. Aging is a continuation of growth. It has no purpose and is an unintended continuation of the body’s development programs that do not go off after development is complete. As a result, aging causes diseases. The anti-aging drug rapamycin has been reported how to cure cancer and increase a patient’s life span. Here is how rapamycin works and Mikahial Blagloskloony’s take on the future of oncology.

The Biology Behind Rapamycin

Cancer is one of the most common aging related diseases. Interventions such as calorie restrictions slow aging and are also known to delay cancer. Rapamycin has a stronger effect than calorie restriction, it prevents MTOR. The initials MTOR stand for “Mammalian Target of Rapamycin”. Aging is dependent on MTOR. This pathway is activated by hormones, growth factors, oxygen, nutrients, and health conditions like obesity. Since rapamycin inhibits MTOR it is capable of extending life span and delaying cancer. Rapamycin delays geroconversion. This is the cellular basis of aging. However, rapamycin is modestly effective in treating cancer and must be used with a combination of other drugs. For rapamycin to be effective in treating cancer, it needs to be started before cancer is initiated. This means if the treatment begins too late in one’s life, its anti-cancer and life prolonging effects will be reduced.

Mikhail’s Plans For Oncology

Mikahil Blagoskloony is renowned as a professor, researcher, and philanthropist. Mikhail is no superman. He is an ordinary person who is striving to ensure individuals worldwide to gain access to the best possible treatment. Mikhail’s specific interest is in themedical research particularly on the cure for cancer and aging. Mikhail has been studying the connection of cancer and aging. He has noted that cancer is common when individuals reach a certain age. Mikhail continues to carry out his research within the field of oncology. Mikhail is not only a researcher; he is very influential in the field of oncology and has inspired his students and peers who want to expand their research in future.Mikhail Blagoskloony’s main goal is to find a way to treat cancer in an effective way that will not be expensive and excruciating for the average person. Mikhail hopes he will find a way of eliminating cancerous cells without destroying normal cells which are important for recovering the body and mind after months of cancer therapy.